Incidence and risk factor for infection of totally implantable venous access port

Background Totally implantable venous access ports (TIVAP) have been widely used in cancer patients for many years. The early infection (within 30 days after TIVAP implantation) rate of TIVAP accounts for about one-third of all TIVAP infections, and early infection often causes port removal and affe...

Full description

Saved in:
Bibliographic Details
Published in:Langenbeck's archives of surgery 2022-02, Vol.407 (1), p.343-351
Main Authors: Chang, Tung-Cheng, Yen, Min-Hsuan, Kiu, Kee-Thai
Format: Article
Language:English
Subjects:
Abdominal Surgery
Adult
Cardiac Surgery
Catheter-Related Infections - epidemiology
Catheterization, Central Venous - adverse effects
Catheters, Indwelling - adverse effects
General Surgery
Humans
Incidence
Medicine
Medicine & Public Health
Original Article
Risk Factors
Thoracic Surgery
Traumatic Surgery
Vascular Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Totally implantable venous access ports (TIVAP) have been widely used in cancer patients for many years. The early infection (within 30 days after TIVAP implantation) rate of TIVAP accounts for about one-third of all TIVAP infections, and early infection often causes port removal and affects subsequent cancer treatment. This study investigated the incidence and risk factors for early and late infection after TIVAP implantation. Methods From January 2013 to December 2018, all adult cancer patients who received TIVAP implantation in Taipei Medical University Shuang-Ho Hospital were reviewed. We evaluated the incidence of TIVAP-related infection, patient characteristics, and bacteriologic data. Univariable analysis and multiple logistic regression analysis were used to evaluate the risk factors of TIVAP-related infection. Results A total of 3001 TIVAPs were implanted in 2897 patients, and the median follow-up time was 424 days (range: 1–2492 days), achieving a combined total of 1,648,731 catheter days. Thirty-one patients (1.0%) had early infection and 167 (5.6%) patients had late infection. In multivariate analysis, TIVAP combined with other surgeries ( p  = 0.03) and inpatient setting ( p  
ISSN:1435-2443
1435-2451
DOI:10.1007/s00423-021-02328-0